Summit Therapeutics Inc.

Summit Therapeutics is a biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutic medicines. The company's primary focus is its lead development candidate, ivonescimab, a bispecific antibody that combines PD-1 blockade with anti-angiogenic properties for treating solid tumors. Ivonescimab is currently in phase III clinical trials across multiple indications, including first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with epidermal growth factor receptor mutations, first-line metastatic NSCLC, and first-line unresectable metastatic colorectal cancer. The company is also evaluating ivonescimab in combination with chemotherapy across these same indications.

Summit Therapeutics operates with approximately 265 full-time employees and maintains its headquarters in Miami, Florida. The company has established a geographic footprint spanning North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa regions to support its clinical development and commercialization activities. Founded in 2003, the company is listed on Nasdaq with a market capitalization of $12.4 billion, reflecting investor interest in its immunotherapy pipeline and the commercial potential of its bispecific antibody platform.